{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:02:18Z","timestamp":1761955338414,"version":"build-2065373602"},"reference-count":33,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:p>Hemolytic uremic syndrome (HUS) is a complication of Shiga toxin\u2013producing Escherichia coli (STEC) infection that can cause acute renal failure and introduce serious extrarenal organ injury. The most life threatening of these include cardiac failure and thrombocytopenia. Here, we present a case of severe STEC-HUS in a previously healthy 2-year-old boy who progressed to cardiac failure necessitating extracorporeal membrane oxygenation (ECMO). Following ECMO cannulation, he was treated with eculizumab, an anticomplement component 5 monoclonal antibody. The patient required ECMO for 5\u00a0days and subsequently survived decannulation with normal cardiac function and a good neurological outcome. This case illustrates the feasibility of ECMO despite the consumptive thrombocytopenia characteristic of HUS as well as the potential role of eculizumab in facilitating cardiac recovery. Additionally, we propose anticoagulation parameters balancing HUS-related thrombocytopenia with hemorrhagic complications while on ECMO. Further studies are warranted to better understand complement dysregulation in the pathophysiology of STEC-HUS and develop treatment guidelines for STEC-HUS with cardiac manifestations.<\/jats:p>","DOI":"10.1542\/peds.2024-070247","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:02:36Z","timestamp":1760572956000},"source":"Crossref","is-referenced-by-count":0,"title":["Extracorporeal Membrane Oxygenation and Eculizumab for Cardiac Failure in STEC-HUS"],"prefix":"10.1542","volume":"156","author":[{"given":"Marissa Y.","family":"Chou","sequence":"first","affiliation":[{"name":"1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eesha","family":"Natarajan","sequence":"additional","affiliation":[{"name":"1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Connolly","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Caffarelli","sequence":"additional","affiliation":[{"name":"1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Henry","sequence":"additional","affiliation":[{"name":"1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren D.","family":"Sacks","sequence":"additional","affiliation":[{"name":"1Division of Critical Care, Department of Pediatrics, University of California San Francisco, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"suppl 5","key":"2025103119573341800_r1","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1093\/cid\/cis208","article-title":"Strategies for surveillance of pediatric hemolytic uremic syndrome: Foodborne Diseases Active Surveillance Network (FoodNet), 2000\u20132007","volume":"54","author":"Ong","year":"2012","journal-title":"Clin Infect Dis."},{"key":"2025103119573341800_r2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpeds.2021.03.067","article-title":"Cardiac manifestation among children with hemolytic uremic syndrome","volume":"235","author":"Sanders","year":"2021","journal-title":"J Pediatr."},{"issue":"3","key":"2025103119573341800_r3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO adult and pediatric anticoagulation guidelines","volume":"68","author":"McMichael","year":"2022","journal-title":"ASAIO J."},{"issue":"2","key":"2025103119573341800_r4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PCC.0000000000002102","article-title":"Platelet transfusion practice and related outcomes in pediatric extracorporeal membrane oxygenation","volume":"21","author":"Cashen","year":"2020","journal-title":"Pediatr Crit Care Med."},{"issue":"3","key":"2025103119573341800_r5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"issue":"3","key":"2025103119573341800_r6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nrneph.2013.280","article-title":"Cardiovascular complications in atypical haemolytic uraemic syndrome","volume":"10","author":"Noris","year":"2014","journal-title":"Nat Rev Nephrol."},{"issue":"12","key":"2025103119573341800_r7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00431-016-2790-y","article-title":"Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature","volume":"175","author":"Rigamonti","year":"2016","journal-title":"Eur J Pediatr."},{"issue":"1","key":"2025103119573341800_r8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol."},{"issue":"2","key":"2025103119573341800_r9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40272-022-00555-6","article-title":"Pharmacological management of atypical hemolytic uremic syndrome in pediatric patients: current and future","volume":"25","author":"Gurevich","year":"2023","journal-title":"Paediatr Drugs."},{"issue":"2","key":"2025103119573341800_r10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1744-9987.12768","article-title":"Is plasma exchange efficacious in Shiga toxin-associated hemolytic uremic syndrome? A narrative review of current evidence","volume":"23","author":"Keenswijk","year":"2019","journal-title":"Ther Apher Dial."},{"issue":"11","key":"2025103119573341800_r11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00467-017-3736-y","article-title":"HUS-induced cardiac and circulatory failure is reversible using cardiopulmonary bypass as rescue","volume":"32","author":"Andersen","year":"2017","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"2025103119573341800_r12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/adc.72.1.46","article-title":"Myocarditis and haemolytic uraemic syndrome","volume":"72","author":"Abu-Arafeh","year":"1995","journal-title":"Arch Dis Child."},{"issue":"2","key":"2025103119573341800_r13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ndt\/gfn649","article-title":"Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome","volume":"24","author":"Mohammed","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"2025103119573341800_r14","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1007\/s00467-022-05427-2","article-title":"Cardiac involvement in pediatric hemolytic uremic syndrome","volume":"37","author":"Tann\u00e9","year":"2022","journal-title":"Pediatr Nephrol."},{"issue":"6","key":"2025103119573341800_r15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00467-013-2414-y","article-title":"Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome","volume":"28","author":"Balestracci","year":"2013","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"2025103119573341800_r16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tmrv.2016.06.004","article-title":"Clinical and laboratory consequences of platelet transfusion in Shiga toxin-mediated hemolytic uremic syndrome","volume":"31","author":"Beneke","year":"2017","journal-title":"Transfus Med Rev."},{"issue":"26","key":"2025103119573341800_r17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med."},{"issue":"24","key":"2025103119573341800_r18","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","article-title":"Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement","volume":"94","author":"Pape","year":"2015","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"2025103119573341800_r19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00467-023-06102-w","article-title":"Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement","volume":"39","author":"Wildes","year":"2024","journal-title":"Pediatr Nephrol."},{"issue":"8","key":"2025103119573341800_r20","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","article-title":"Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study","volume":"33","author":"Percheron","year":"2018","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"2025103119573341800_r21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant."},{"issue":"8","key":"2025103119573341800_r22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dmcn.12161","article-title":"Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab","volume":"55","author":"Gitiaux","year":"2013","journal-title":"Dev Med Child Neurol."},{"issue":"5","key":"2025103119573341800_r23","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00467-023-06216-1","article-title":"Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review","volume":"39","author":"de Zwart","year":"2024","journal-title":"Pediatr Nephrol."},{"issue":"15","key":"2025103119573341800_r24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga toxin-producing Escherichia coli and the hemolytic-uremic syndrome","volume":"389","author":"Freedman","year":"2023","journal-title":"N Engl J Med."},{"issue":"3","key":"2025103119573341800_r25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/archdischild-2016-311377","article-title":"Treatment and management of children with haemolytic uraemic syndrome","volume":"103","author":"Walsh","year":"2018","journal-title":"Arch Dis Child."},{"issue":"3","key":"2025103119573341800_r26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00431-017-3077-7","article-title":"Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence","volume":"177","author":"Keenswijk","year":"2018","journal-title":"Eur J Pediatr."},{"key":"2025103119573341800_r27","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ."},{"issue":"12","key":"2025103119573341800_r28","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","article-title":"Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study","volume":"35","author":"Monet-Didailler","year":"2020","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"2025103119573341800_r29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/toxins13050306","article-title":"Shiga toxin-associated hemolytic uremic syndrome: specificities of adult patients and implications for critical care management","volume":"13","author":"Travert","year":"2021","journal-title":"Toxins (Basel)."},{"issue":"9","key":"2025103119573341800_r30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","article-title":"Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020","volume":"69","author":"Mbaeyi","year":"2020","journal-title":"MMWR Recomm Rep."},{"issue":"4","key":"2025103119573341800_r31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/2040620715577613","article-title":"Advances and challenges in the management of complement-mediated thrombotic microangiopathies","volume":"6","author":"Davin","year":"2015","journal-title":"Ther Adv Hematol."},{"issue":"9","key":"2025103119573341800_r32","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J Am Soc Nephrol."},{"key":"2025103119573341800_r33","article-title":"Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT","volume":"11","author":"Ives","year":"2024","journal-title":"Efficacy Mech Eval."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070247\/1863077\/pediatrics.2024070247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070247\/1863077\/pediatrics.2024070247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:57:40Z","timestamp":1761955060000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/156\/5\/e2024070247\/204576\/Extracorporeal-Membrane-Oxygenation-and-Eculizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-070247","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"e2024070247"}}